Davis Selected Advisers’s Sinovac Biotech SVA Stock Holding History
Bought
Maintained
Sold
Other funds holding SVA
Davis Selected Advisers's SVA Position: Q3 2014 in Review
Davis Selected Advisers sold out of Sinovac Biotech (SVA) in Q3 2014, closing a stake of 1,250,546 shares — an estimated $7.05M sold.
Davis Selected Advisers first reported a position in SVA in Q2 2013 and held it in 5 quarters. The position peaked at $10.3M in Q2 2013. 45 funds tracked by Wall St. Rank hold SVA as of Q3 2014.
- Davis Selected Advisers reported no remaining Sinovac Biotech position as of Q3 2014 after selling out during the quarter.
- Davis Selected Advisers sold 1,250,546 Sinovac Biotech shares in Q3 2014, an estimated $7.05M.
- Davis Selected Advisers first reported a position in Sinovac Biotech in Q2 2013 and held it in 5 quarters.
- Davis Selected Advisers's Sinovac Biotech position peaked at $10.3M in Q2 2013.
- 45 funds tracked by Wall St. Rank held Sinovac Biotech as of Q3 2014.
Based on Davis Selected Advisers's 13F filing for Q3 2014, filed 12 Nov 2014.